<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329950</url>
  </required_header>
  <id_info>
    <org_study_id>CDX1140-01</org_study_id>
    <secondary_id>Keynote-A23</secondary_id>
    <nct_id>NCT03329950</nct_id>
  </id_info>
  <brief_title>A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or
      in combination with CDX-301, pembrolizumab, or chemotherapy and to further evaluate its
      tolerability and efficacy in expansion cohorts once the MTD is determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability
      and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2),
      pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer.

      Eligible patients that enroll to the dose-escalation portion of the study will be assigned to
      one of several dose levels of CDX-1140. The dose-escalation part of the study will test the
      safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or
      chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion
      portions of the study.

      All patients enrolled in the study will be closely monitored to determine if there is a
      response to the treatment as well as for any side effects that may occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0</measure>
    <time_frame>From first dose through 30 days after last dose</time_frame>
    <description>The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years.</time_frame>
    <description>The percentage of patients who achieved a confirmed complete response or partial response by evaluation criteria in solid tumors for immune-based therapeutics (iRECIST; for solid tumor patients) and the lymphoma response to immunomodulatory therapy criteria (LYRIC; for lymphoma patients).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Every 8-12 weeks, starting with first dose until disease progression, assessed up to approximately 1-3 years</time_frame>
    <description>The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>First occurrence of a documented objective response to disease progression or death (up to approximately 1-3 years)</time_frame>
    <description>The interval from which measurement criteria are first met for CR or PR until the first date that progressive disease is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 1-3 years)</time_frame>
    <description>The time from start of study drug to time of progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from start of study drug to death from any cause (up to approximately 1-3 years)</time_frame>
    <description>The time from start of study drug to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity evaluation</measure>
    <time_frame>Prior to each dose of study treatment and at treatment discontinuation, up to approximately 1-3 years</time_frame>
    <description>Serum samples will be obtained for assessment of human anti-CDX-1140 and anti-CDX-301 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Prior to each study treatment, multiple timepoints after each study treatment, and at treatment discontinuation up to approximately 1-3 years</time_frame>
    <description>CDX-1140 and CDX-301 concentrations will be measured</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Bladder Urothelial Carcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Hepatic Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Other Solid Tumors</condition>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Indolent B-cell Lymphomas</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CDX-1140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-1140</intervention_name>
    <description>CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.</description>
    <arm_group_label>CDX-1140</arm_group_label>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-301</intervention_name>
    <description>CDX-301 will be injected once a day for five days before Cycles 1 and 2.</description>
    <arm_group_label>CDX-1140 and CDX-301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered every 3 weeks.</description>
    <arm_group_label>CDX-1140 and pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.</description>
    <arm_group_label>CDX-1140 and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular),
             bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast,
             colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary
             peritoneal carcinoma, head and neck, and cholangiocarcinoma. Additional tumor types
             (except primary CNS tumors) may be enrolled after discussion with, and approval from,
             the medical monitor.

          2. Must have received all standard of care therapies (approved or unapproved) as deemed
             appropriate by the treating physician. Patients who refuse standard therapy are
             excluded from the study.

          3. If of childbearing potential (male or female), agrees to practice an effective form of
             contraception during study treatment and for at least 3 months following last
             treatment

          4. Willingness to undergo a pre-treatment and on-treatment biopsy, if required.

        Additional Inclusion Criteria for Part 1:

          1. Advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, or indolent
             B-cell lymphoma are also eligible.

          2. Lymphoma patients must have received ≥ 1 prior systemic therapy

        Additional Inclusion Criteria for Part 3:

          1. Patients must have documented progression while receiving anti-PD-1 or anti-PD-L1
             based regimens for FDA approved indications

          2. Patients cannot have received more than one anti-PD-1 or anti-PD-L1 based regimen

        Additional Inclusion Criteria for Part 4:

        1. Patients must have metastatic pancreatic adenocarcinoma, and have not received previous
        treatment in a metastatic setting

        Key Exclusion Criteria:

          1. History of severe hypersensitivity reactions to other monoclonal antibodies.

          2. Previous treatment with any anti-CD40 antibody or with FLT3L.

          3. Inadequate washout period from prior therapy as defined in the Protocol.

          4. Major surgery within 4 weeks prior to study treatment.

          5. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within
             2 weeks prior to study treatment.

          6. Other prior malignancy, except for adequately treated basal or squamous cell skin
             cancer or in situ cancers. For all other cancers, the patient must be disease-free for
             at least 3 years to be allowed to enroll.

          7. Active, untreated central nervous system metastases.

          8. Active autoimmune disease or documented history of autoimmune disease.

          9. History of (non-infectious) pneumonitis or has current pneumonitis.

         10. Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or
             Hepatitis C.

        Additional Exclusion Criteria for lymphoma patients in Part 1:

          1. Prior allogenic stem cell transplantation

          2. Patients who have received autologous stem cell transplant ≤ 12 weeks prior to the
             first dose of study drug.

        There are additional criteria your study doctor will review with you to confirm your
        eligibility for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Insititute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gordon, MD</last_name>
      <phone>480-323-1350</phone>
      <email>Michael.Gordon@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Dan Mocan</last_name>
      <phone>480-323-3661</phone>
      <email>dmocan@honorhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <phone>404-303-3355</phone>
      <email>clinicaltrials@northside.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jenkins</last_name>
      <phone>706-721-1206</phone>
      <email>kjenkins@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Loveday</last_name>
      <phone>706-721-5095</phone>
      <email>ploveday@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vamsi Kota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West, PC dba Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
    <contact_backup>
      <last_name>Gladys Pierce</last_name>
      <phone>402-691-6972</phone>
      <email>gpierce@nebraskacancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Delbeau, MSN, AGCNS-BC, RN</last_name>
      <phone>212-824-7811</phone>
      <email>Daniela.Delbeau@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Bhardwaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Khalil, MD</last_name>
      <phone>646-888-4384</phone>
      <email>khalild@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Danny Khalil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Brittany Dessecker</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>213</phone_ext>
      <email>bdessecker@gabrailcancercenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher, RN</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.Fisher@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Tara Foote, RN</last_name>
      <phone>503-215-7192</phone>
      <email>Tara.Foote@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center at the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagan Loburak</last_name>
      <phone>215-614-7677</phone>
      <email>Sagan.Loburak@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Louie</last_name>
      <phone>215-220-9668</phone>
      <email>Jennifer.Louie2@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark O'Hara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital (RIH) The Miriam Hospital (TMH)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kuhlman, MBA, BS, BA</last_name>
      <phone>401-444-5014</phone>
      <email>RKuhlman@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Adam Olszewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maen Abdelrahim, MD</last_name>
      <phone>713-441-9948</phone>
      <email>mabdelrahim@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Guthrie</last_name>
      <phone>713-441-6564</phone>
      <email>mlguthrie@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maen Abdelrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX-1140</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>GI Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Celldex</keyword>
  <keyword>Monoclonal</keyword>
  <keyword>Antibody</keyword>
  <keyword>CD40</keyword>
  <keyword>CD-40</keyword>
  <keyword>Flt3l</keyword>
  <keyword>CDX-301</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Bile duct cancer</keyword>
  <keyword>TNBC</keyword>
  <keyword>RCC</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Dendritic cell</keyword>
  <keyword>Keynote A-23</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

